- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00928421
An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
April 19, 2021 updated by: Boston Scientific Corporation
An Open-label, Single-dose Pilot Study to Evaluate the Efficacy and Safety of Varisolve® (Polidocanol Endovenous Microfoam) 0.125% [0.2%] for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence
To determine the effect and safety of Varisolve® 0.125% [0.2%]
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In patients with SFJ incompetence due to reflux of the Great Saphenous Vein (GSV) or major accessory veins, with venous disease manifested by both symptoms and visible varicosities: using duplex ultrasonography, to evaluate the efficacy of Varisolve® 0.125% [0.2%] as assessed by the elimination of SFJ reflux and/or occlusion of the treated vein
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Bellevue, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female; age of consent to 75 years
- Baseline VEINES-Sym Questionnaire score less than 75 points
- Superficial venous disease manifested by both symptoms and visible varicosities
- Varicose vein clinical classification CEAP 2 through 5
- Incompetence of SFJ (reflux > 0.5 seconds on duplex ultrasonography) associated with incompetence of the great saphenous vein (GSV) or other major accessory vein
- Ability to comprehend and sign an informed consent document and complete study questionnaires in English
Exclusion Criteria:
- Incompetence of the small saphenous vein (SSV)
- Ultrasonographic or other evidence of current or previous deep vein thrombosis, occlusion or incompetence
- Leg obesity impairing the ability to access the vein to be treated and/or to follow the post-procedural compression recommendations.
- Peripheral arterial disease in the leg to be treated contraindicating post-procedural compression.
- Reduced mobility (inability to maintain a brisk walk unaided for a minimum of 5 minutes per hour per day).
- Planned prolonged automobile, bus, or air travel within 4 weeks following treatment, unless the patient can walk for at least 5 consecutive minutes every hour during travel.
- History of pulmonary embolism or stroke.
- Major surgery, prolonged hospitalization or pregnancy within 3 months of screening.
- Current anticoagulation therapy (within 7 days of enrollment).
- Participation in a clinical study involving an investigational pharmaceutical product or device within the 3 months prior to screening.
- Previous treatment in this study or in a previous Varisolve® study.
- Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.) or clinically significant laboratory abnormalities.
- Known allergic response to polidocanol, or severe and multiple allergic reactions.
- Women of childbearing potential not using effective contraception for at least one month prior to study enrollment and/or unwilling to continue birth control until their last study visit.
- Pregnant or lactating women.
- Current alcohol or drug abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Varisolve 0.125%
|
Polidocanol Endovenous Microfoam 0.125%, single dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Responders to Treatment, Assessed by Duplex Ultrasound
Time Frame: 8 weeks
|
Responders; elimination of reflux through the saphenofemoral junction and/or coplete occlusion of the great saphenous vein at 8 weeks, as measured by duplex ultrasound.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Ellen Evans, BTG International Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (ACTUAL)
December 1, 2009
Study Completion (ACTUAL)
January 1, 2010
Study Registration Dates
First Submitted
June 24, 2009
First Submitted That Met QC Criteria
June 25, 2009
First Posted (ESTIMATE)
June 26, 2009
Study Record Updates
Last Update Posted (ACTUAL)
May 13, 2021
Last Update Submitted That Met QC Criteria
April 19, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAP.VV014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Varicose Veins
-
EMSWithdrawn
-
EMSWithdrawn
-
I-VASC S.r.lRecruiting
-
Acotec Scientific Co., LtdZhejiang UniversityCompletedVaricose Veins of Lower LimbChina
-
Beijing Tsinghua Chang Gung HospitalActive, not recruiting
-
Oulu University HospitalCompletedVaricose Veins | Varicose Veins of Lower LimbFinland
-
Kahramanmaras Sutcu Imam UniversityUnknown
-
Helsinki University Central HospitalActive, not recruiting
-
The Fourth Affiliated Hospital of Zhejiang University...RecruitingVaricose Veins of Lower LimbChina
-
Peking University People's HospitalPeking University First Hospital; First Affiliated Hospital Xi'an Jiaotong... and other collaboratorsActive, not recruiting
Clinical Trials on Polidocanol Endovenous Microfoam 0.125%
-
Boston Scientific CorporationCompletedGreat Saphenous Vein Incompetence | Visible VaricositiesUnited States
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationBTG International Inc.Completed
-
OhioHealthBTG International Inc.WithdrawnLeg Ulcer | Varicose Veins | Varicose Ulcer | Venous Leg Ulcer | Venous Reflux | Reflux | Venous Ulcer | Veins, Varicose | Varicose Veins LegUnited States
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationCompleted
-
Imperial College LondonTerminated
-
ProMedica Health SystemJobst Vascular InstituteRecruitingVenous Insufficiency | Venous Reflux | Venous Ulcer | Venous DiseaseUnited States
-
Societe Francaise de PhlebologieCompletedVaricose Veins of Lower Limb